美国 · SEC FORM 4
Avalo Therapeutics, Inc.
AVTX · Nasdaq · CIK 0001534120 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
65 同一窗口内观察到的 Form 4 交易行
34 sales · 31 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2024-11-13 · Almenoff June Sherie.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息，不影响内部人信号。
价格表现
- 1M
- -17.9%
- 3M
- -28.1%
- 6M
- -0.7%
- 12M
- -11.6%
波动率与流动性
- 波动率
- 85.8%
- Beta
- —
- 平均每日成交额
- USD 12.2M
估值
- 市值
- USD 710.1M
- P/E
- —
基本面
- 利润率
- —
- ROE
- -94.2%
- 细分行业
- Biotechnology
市场数据
价格数据截至：2026-10-12 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值, ROE · 财年截止日：2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-08-03 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 11,405,304
- 上期报告
- 12,925,869
- 日均成交量
- 1,296,416
- 回补天数
- 8.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2024-11-13 | Almenoff June Sherie | 买入 (P) | Common Stock | 500 | USD 13.00 | USD 6,500 | SEC 申报 ↗ |
| 2024-11-12 | Almenoff June Sherie | 买入 (P) | Common Stock | 500 | USD 12.50 | USD 6,250 | SEC 申报 ↗ |
| 2023-06-26 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 1,608,000 | USD 0.64 | USD 1,025,474 | SEC 申报 ↗ |
| 2023-06-20 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 2,000 | USD 4.14 | USD 8,280 | SEC 申报 ↗ |
| 2023-06-16 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 3,000 | USD 3.90 | USD 11,700 | SEC 申报 ↗ |
| 2023-06-15 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 3,160 | USD 3.68 | USD 11,629 | SEC 申报 ↗ |
| 2023-06-14 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 6,000 | USD 3.48 | USD 20,880 | SEC 申报 ↗ |
| 2023-06-13 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 8,750 | USD 3.82 | USD 33,425 | SEC 申报 ↗ |
| 2023-06-12 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 2,149 | USD 4.34 | USD 9,327 | SEC 申报 ↗ |
| 2023-06-09 | Sullivan Christopher Ryan | 买入 (P) | Common Stock | 511 | USD 3.42 | USD 1,748 | SEC 申报 ↗ |
| 2023-06-09 | NEIL GARRY ARTHUR | 买入 (P) | Common Stock | 4,000 | USD 3.42 | USD 13,680 | SEC 申报 ↗ |
| 2023-06-09 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 5,044 | USD 4.14 | USD 20,882 | SEC 申报 ↗ |
| 2023-06-08 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 6,398 | USD 3.93 | USD 25,144 | SEC 申报 ↗ |
| 2023-06-07 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 2,984 | USD 3.49 | USD 10,414 | SEC 申报 ↗ |
| 2023-05-31 | Caissa Capital Management ltd. | 买入 (P) | Common Stock | 844 | USD 2.87 | USD 2,422 | SEC 申报 ↗ |
Form 4 申报证据
92 transaction lines in the latest 365-day window; 236 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 12,394 | USD 16.33 | USD 202,394 | SEC 申报 ↗ |
| 2026-09-16 | Sullivan Christopher Ryan | 期权行权／转换 (M) | Common Stock | 12,394 | USD 9.88 | USD 122,453 | SEC 申报 ↗ |
| 2026-09-10 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 10,185 | USD 17.62 | USD 179,460 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 12,394 | USD 16.33 | USD 202,394 | SEC 申报 ↗ |
| 2026-09-16 | Sullivan Christopher Ryan | 期权行权／转换 (M) | Common Stock | 12,394 | USD 9.88 | USD 122,453 | SEC 申报 ↗ |
| 2026-09-10 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 10,185 | USD 17.62 | USD 179,460 | SEC 申报 ↗ |
| 2026-09-10 | Sullivan Christopher Ryan | 期权行权／转换 (M) | Common Stock | 10,185 | USD 8.04 | USD 81,887 | SEC 申报 ↗ |
| 2026-08-28 | Doyle Mittie | 卖出 (S) | Common Stock | 679 | USD 20.00 | USD 13,580 | SEC 申报 ↗ |
| 2026-08-28 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 679 | USD 8.04 | USD 5,459 | SEC 申报 ↗ |
| 2026-08-18 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 31,031 | USD 20.05 | USD 622,172 | SEC 申报 ↗ |
| 2026-08-18 | Sullivan Christopher Ryan | 期权行权／转换 (M) | Common Stock | 31,031 | USD 9.88 | USD 306,586 | SEC 申报 ↗ |
| 2026-08-17 | Sullivan Christopher Ryan | 卖出 (S) | Common Stock | 41,694 | USD 19.86 | USD 827,963 | SEC 申报 ↗ |
| 2026-08-17 | Sullivan Christopher Ryan | 期权行权／转换 (M) | Common Stock | 40,821 | USD 9.88 | USD 403,311 | SEC 申报 ↗ |
| 2026-08-17 | Doyle Mittie | 卖出 (S) | Common Stock | 1,000 | USD 20.00 | USD 20,000 | SEC 申报 ↗ |
| 2026-08-17 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 1,000 | USD 12.65 | USD 12,650 | SEC 申报 ↗ |
| 2026-08-11 | Riley Jennifer | 卖出 (S) | Common Stock | 2,655 | USD 19.59 | USD 52,011 | SEC 申报 ↗ |
| 2026-08-10 | Doyle Mittie | 卖出 (S) | Common Stock | 679 | USD 20.00 | USD 13,580 | SEC 申报 ↗ |
| 2026-08-10 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 679 | USD 8.04 | USD 5,459 | SEC 申报 ↗ |
| 2026-07-27 | Doyle Mittie | 卖出 (S) | Common Stock | 1,000 | USD 20.00 | USD 20,000 | SEC 申报 ↗ |
| 2026-07-27 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 1,000 | USD 12.65 | USD 12,650 | SEC 申报 ↗ |
| 2026-06-30 | Doyle Mittie | 卖出 (S) | Common Stock | 4,654 | USD 20.00 | USD 93,080 | SEC 申报 ↗ |
| 2026-06-30 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 4,654 | USD 10.89 | USD 50,672 | SEC 申报 ↗ |
| 2026-06-23 | Doyle Mittie | 卖出 (S) | Common Stock | 1,450 | USD 18.00 | USD 26,100 | SEC 申报 ↗ |
| 2026-06-23 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 1,450 | USD 8.04 | USD 11,658 | SEC 申报 ↗ |
| 2026-06-10 | VARKI PAUL | 代扣税 (F) | Common Stock | 1,081 | USD 13.10 | USD 14,161 | SEC 申报 ↗ |
| 2026-06-10 | Sullivan Christopher Ryan | 代扣税 (F) | Common Stock | 138 | USD 13.10 | USD 1,808 | SEC 申报 ↗ |
| 2026-06-10 | Riley Jennifer | 代扣税 (F) | Common Stock | 588 | USD 13.10 | USD 7,703 | SEC 申报 ↗ |
| 2026-06-10 | Doyle Mittie | 代扣税 (F) | Common Stock | 1,084 | USD 13.10 | USD 14,200 | SEC 申报 ↗ |
| 2026-05-28 | Doyle Mittie | 卖出 (S) | Common Stock | 679 | USD 16.00 | USD 10,864 | SEC 申报 ↗ |
| 2026-05-28 | Doyle Mittie | 期权行权／转换 (M) | Common Stock | 679 | USD 8.04 | USD 5,459 | SEC 申报 ↗ |
| 2026-05-21 | VARKI PAUL | 奖励／授予 (A) | Common Stock | 24,300 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | Sullivan Christopher Ryan | 奖励／授予 (A) | Common Stock | 39,900 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-21 | Riley Jennifer | 奖励／授予 (A) | Common Stock | 34,200 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AVTX |
| CIK | 0001534120 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 236 transaction lines from 2020-01-22 to 2026-09-16 121 P purchase lines · 45 S sale lines · 70 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.